New video: a brief introduction to NVIDIA's BioNeMo, OpenAI's GPT-Rosalind, and Anthropic's Claude Science. While they all sell "AI-powered drug discovery", they are in fact very different products. youtu.be/NQvWXcYszMI #artificialintelligence #bioinformatics #drugdiscovery

Transparent. Trustworthy. Rigorous. Follow @MedvoltAI for insights on the future of drug discovery. 🌐 medvolt.ai #Medvolt #MedGraph #Oopal #TrustworthyAI #DrugDiscovery #AIinPharma

Great to see machine learning frameworks like DPA-3 accelerating force field optimization! Achieving both efficiency and precision is a game-changer for scaling up accurate biomolecular simulations. Outstanding work! 🧬💻 #CompChem #DrugDiscovery

Regeneron presented Phase III NIMBLE data on cemdisiran in generalized myasthenia gravis at EAN 2026: disease control, not an approval. #Pharma #Biopharma #Drugs #DrugDiscovery #Heath #FreshNews #FreshPharmaNews

The biggest challenge in researching rare diseases lies not only in diagnosis and treatment but also in developing appropriate models to test potential drug molecules and interventions. Factors such as the young age of affected children, the rarity of the condition, and limited funding all contribute to these challenges. However, we are actively working to overcome these barriers. We have brought children from various parts of the world to our platform and created neuronal models to accelerate the pace of research. Contact us to learn more about our platform for mitochondrial rare diseases. hubs.la/Q04nyMdS0 #MitochondrialDisease #Neuroscience #StemCells #POLG #DrugDiscovery #POLG #NeuroResearch Stemnovate Limited

Manual synthesis planning = days lost before a single reaction runs. MolRetro fixes that. Target molecule → ranked synthesis routes in minutes. Literature AI-generated routes, unified. Stock checked in real time. #DrugDiscovery #AIinPharma #Retrosynthesis

The changing landscape for drug discovery investment ddw-online.com/the-changing-… Follow DDW; Business insights for the global scientific community #DrugDiscovery

The closer a model reflects human biology, the better the research outcomes. #didyouknow #hepatocytes #drugdiscovery #adme #Kosheeka

📚MedChemExpress Digest | #KRAS-Targeted Cancer Research The field of KRAS signaling has rapidly evolved beyond “druggability” into mutation-driven precision therapies. Early KRAS G12C inhibitors validated KRAS as a target, but also exposed key challenges including resistance, adaptive signaling, and tumor microenvironment remodeling. 🚀 New strategies are expanding the landscape: • KRAS G12D inhibitors • RAS(ON) inhibitors • Pan-RAS approaches #ASCO2026 data (e.g., #Daraxonrasib) further highlights the shift toward broader coverage and improved clinical outcomes. Beyond inhibition, emerging modalities such as protein degradation, RNA therapeutics, and synthetic lethality are reshaping intervention strategies. 🌱 The next phase focuses on overcoming resistance, expanding mutation coverage, and improving durability through tumor ecosystem remodeling. Discover more: ow.ly/HP5M50Zkx7k #Oncology #CancerResearch #DrugDiscovery #PrecisionMedicine

💊#FDAApproval Update | The #FDA has expanded the approval of #Casgevy (#exagamglogene autotemcel), making it the first gene therapy approved for children aged 2 years and older with #SickleCellDisease (#SCD) and recurrent vaso-occlusive crises. 💡Casgevy is the first FDA-approved CRISPR/Cas9 gene-editing therapy, designed to increase fetal hemoglobin (HbF) production and reduce the sickling of red blood cells. 🩸Sickle cell disease is a life-threatening inherited blood disorder that can cause severe pain, organ damage, and reduced life expectancy, often beginning in early childhood. Read more: fda.gov/news-events/press-an… #SickelCell #GeneTherapy #CRISPR #Hematology #RareDisease #DrugDiscovery #MedicinalChemistry

#CancerResearch #DrugDiscovery go.nature.com/4v2NtgI

Should an AI company develop its own drugs for diseases pharma ignores? 🧠 NEW: @AnthropicAI paired two announcements, Claude Science (a workbench unifying 60 scientific tools and databases for genomics, proteomics, and chemistry) and, more strikingly, its own in-house preclinical drug-discovery programs. 🔬 The focus is the notable part: neglected diseases, the ones traditional pharma often skips because the market is too small to justify the cost. Anthropic's reasoning is that you can't build serious tools for drugmakers without doing the work yourself, and that a public-benefit mission lets it chase treatments that may never turn a profit. The sober caveats matter too: no disease targets or timelines have been named, preclinical is the cheapest, earliest step of a years-long, billion-dollar process, and the AI drug boom hasn't yet put a single treatment in a patient's hands. A meaningful push for overlooked diseases, or years from proving anything? 👇 #AI #Anthropic #DrugDiscovery #TOAINews2026

300 publications. One global community driving countless discoveries. A new hypothesis. An innovative approach. A deeper insight. A discovery that moves the field forward. Today, more than 300 peer-reviewed publications have used MaxWell Biosystems technology to advance research across neuroscience, disease modeling, drug discovery, neurotechnology, and beyond. Together, these publications represent a global community of researchers using high-density electrophysiology to uncover functional insights at scale. Behind every paper is a team pushing the field forward by: 🔹 Revealing neuronal activity across scales, from network dynamics to subcellular signals 🔹 Detecting early and subtle changes in functional activity 🔹 Studying neural connectivity, maturation, and response over time 🔹 Linking electrophysiology to disease biology and therapeutic insight 🔹 Developing new approaches that push functional neuroscience forward To every scientist, collaborator, user, and partner who has contributed to these to this growing community: thank you. Your curiosity, creativity, and commitment to discovery continue to inspire us. We are proud that our technology enables the science that moves the neuroscience field forward. 📚 Explore the publication library: mxwbio.com/publications #ScientificCommunity #Neuroscience #Electrophysiology #HDMEA #LifeSciences #DrugDiscovery

🧬What happens when a life-changing diagnosis becomes a mission to change the future of drug discovery? 💡As part of BGN’s Bio-Innovation Unit activity, Dr. @Anat_Shperberg and Dr. Maya Shemesh lead the Lunch & Learn lecture series, bringing researchers, entrepreneurs, and industry voices together around the challenges and opportunities of translating science into real-world impact. ⚕️In a recent session, @SagiGidali shared the deeply personal story behind his shift from building and exiting cybersecurity companies to tackling one of the hardest challenges in medicine: accelerating the discovery of treatments for rare genetic diseases. 👶After his son Rafa was diagnosed with STXBP1, Sagi began looking for answers, including research that started at @bengurionu in the lab of Prof. @GVatine. When he was told there was no cure and nothing to be done, his response was to act. 🚀From founding Rafa's Moonshot to building new AI-driven approaches for drug discovery, Sagi’s story highlights what can happen when entrepreneurship, science, urgency, and personal purpose come together. 📼The full lecture recording is available in the first comment. #DrugDiscovery #RareDiseases #AIinHealthcare #Biotech #LifeSciences #HealthInnovation #Entrepreneurship #TranslationalResearch

#India #Hyderabad-based #startup Acubiosys Pvt Ltd. harnesses #AI to develop treatment for #psoriasis: products are result of combining AI-assisted #drugdiscovery with #nanotechnology and biomedical research to create safer and more targeted therapies. newindianexpress.com/cities/…

AI in drug discovery needs more than accurate predictions—it needs trust. Antonio Lavecchia explains why data integrity, validation, explainability, and human oversight are essential for regulatory-ready AI in pharma. pharmafocuseurope.com/articl… #DrugDiscovery #HealthcareInnovation

New Research: Physical feasibility gating in early drug discovery: a decision framework for identifying predictable physical failures, with retrospective illustration frontiersin.org/articles/10.… #FrontiersIn #DrugDiscovery

AI meets nuclear medicine as Sanyou Bio and Baiyunshan Xihe pursue cancer diagnostics pharmadevicenews.com/ai-meet… Explore how @sanyoubio and @BaiyunshanXihe are combining AI discovery and nuclear medicine to advance precision oncology theranostics. #SanyouBio #BaiyunshanXihe #Radiopharmaceuticals #NuclearMedicine #Theranostics #PrecisionOncology #CancerDiagnostics #Biotechnology #DrugDiscovery #MolecularImaging

📖 New Publication Spotlight Asymmetric Total Synthesis and Antihypoxic Neuroinflammatory Evaluation of Notopterol, Notoptol, and Their Natural Analogues This elegant study reports the first asymmetric total synthesis of notopterol, notoptol, and nine natural analogues, featuring a gram-scale BTHL-catalyzed asymmetric vinylogous Mukaiyama–aldol reaction . A subsequent 1,3-rearrangement establishes a plausible biosynthetic relationship between notopterol and notoptol while representing the first application of the BTHL catalytic system to non-Brassard diene substrates. Beyond its synthetic innovation, biological evaluation identified (−)-notopterol and (−)-3 as potent, configuration-dependent antihypoxic neuroinflammatory agents, underscoring the value of asymmetric synthesis in enabling the discovery of new bioactive molecules. Congratulations to Yang et al. on this outstanding contribution to synthetic organic chemistry and drug discovery. pubs.acs.org/doi/10.1021/acs… #AsymmetricSynthesis #TotalSynthesis #NaturalProducts #OrganicSynthesis #MedicinalChemistry #Catalysis #VMAR #DrugDiscovery #Neuroinflammation #CustomSynthesis #CRO #CDMO #ProcessChemistry #ProcessDevelopment

Anthropic has announced it will develop its own drugs focused on neglected diseases. At the same time the company introduced Claude Science, a workbench designed for life sciences research and drug discovery workflows. The Verge covered the story in detail: theverge.com/ai-artificial-i… Claude Science connects researchers to specialized tools and datasets. It supports tasks from protein structure analysis to molecular epidemiology. Early testing included teams at UCSF and Manifold Bio. This approach sets Anthropic apart from most frontier labs. The company sells AI tools to pharmaceutical organizations while running its own internal discovery programs. The same models that serve external customers will also generate proprietary drug candidates. Enterprise AI teams evaluating these capabilities face a clear strategic tension. Advanced models can accelerate internal pipelines and reduce time to candidate selection. Reliance on a provider that competes in the same therapeutic areas requires updated vendor assessments, data segregation rules, and explicit IP protections. Governance frameworks need extension into this domain. AI systems that propose molecular structures introduce requirements for reproducibility, safety validation, and regulatory traceability that general model policies do not address. Organizations must define new controls before deployment. Frontier AI companies continue to expand beyond horizontal platforms. Direct participation in scientific verticals is now part of the model. Drug discovery marks one visible step. Similar patterns will appear in materials, energy, and other capital-intensive fields. #ArtificialIntelligence #DrugDiscovery #Anthropic #Claude #LifeSciences #AIGovernance #EnterpriseAI #Biotech #AIStrategy